|
シミズ タツヤ
SHIMIZU Tatsuya
清水 達也 所属 研究施設 研究施設 職種 教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | The bioengineering of perfusable endocrine tissue with anastomosable blood vessels. |
| 掲載誌名 | 正式名：Biofabrication 略 称：Biofabrication ISSNコード：17585090/17585082 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 15(4),pp.045010 |
| 著者・共著者 | YAGO Hiroki†, HOMMA Jun*, SEKINE Hidekazu*, HIGASHI Yuhei, SAKURAI Hiroyuki, SHIMIZU Tatsuya |
| 担当区分 | 最終著者 |
| 発行年月 | 2023/08 |
| 概要 | Organ transplantation is a definitive treatment for endocrine disorders, but donor shortages limit the use of this technique. The development of regenerative therapies would revolutionize the treatment of endocrine disorders. As is the case for harvested organs, the ideal bioengineered graft would comprise vascularized endocrine tissue, contain blood vessels that could be anastomosed to host vessels, have stable blood flow, and be suitable for transplantation into various sites. Here, we describe a transplantable endocrine tissue graft that was fabricated byex vivoperfusion of tricultured cell sheets (isletβ-cells, vascular endothelial cells (vECs), and mesenchymal stem cells (MSCs)) on a vascularized tissue flap ofin vivoorigin. The present study has three key findings. First, mild hypothermic conditions enhanced the success ofex vivoperfusion culture. Specifically, graft construction failed at 37 °C but succeeded at 32 °C (mild hypothermia), and endocrine tissue fabricated under mild hypothermia contained aggregations of isletβ-cells surrounded by dense vascular networks. Second, the construction of transplantable endocrine tissue byex vivoperfusion culture was better achieved using a vascular flap (VF) than a muscle flap. Third, the endocrine tissue construct generated using a VF could be transplanted into the rat by anastomosis of the graft artery and vein to host blood vessels, and the graft secreted insulin into the host's circulatory system for at least two weeks after transplantation. Endocrine tissues bioengineered using these techniques potentially could be used as novel endocrine therapies. |
| DOI | 10.1088/1758-5090/ace9fc |
| PMID | 37487489 |